Filgotinib
is indicated for the treatment of
moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease‑modifying anti‑rheumatic drugs
(DMARDs). Filgotinib may be used as
monotherapy or in combination with methotrexate (MTX).
